In lean MASLD with sarcopenia or visceral adiposity despite normal BMI, how do you prioritize resistance training/nutrition versus pharmacologic cardiometabolic prevention, and what metrics do you track to decide if the plan is working?

I don't think this is a dichotomous choice, as resistance training and nutrition are complementary to pharmacologic cardiometabolic prevention. From a pharmacologic perspective, I would be cautious with incretin-based therapies as these may worsen sarcopenia, especially in an already lean (i.e., nor...